{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:55:34Z","timestamp":1780437334889,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T00:00:00Z","timestamp":1465257600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"JSPS KAKENHI from the Japanese Government","award":["25462715"],"award-info":[{"award-number":["25462715"]}]},{"name":"JSPS KAKENHI","award":["26462661"],"award-info":[{"award-number":["26462661"]}]},{"DOI":"10.13039\/100008732","name":"the Uehara Memorial Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s10384-016-0454-0","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T08:46:40Z","timestamp":1465289200000},"page":"419-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica"],"prefix":"10.1007","volume":"60","author":[{"given":"Sho","family":"Nobuyoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyasu","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,7]]},"reference":[{"issue":"Suppl 1","key":"454_CR1","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10875-012-9796-7","volume":"33","author":"DM Wingerchuk","year":"2013","unstructured":"Wingerchuk DM. Neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol. 2013;33(Suppl 1):S33\u20137.","journal-title":"J Clin Immunol."},{"key":"454_CR2","first-page":"440","volume":"72","author":"CM Wiles","year":"2002","unstructured":"Wiles CM, Brown P, Chapel H, Guerrini R, Hughes RA, Martin TD, et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry. 2002;72:440\u20138.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"454_CR3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/jns5.12048","volume":"18","author":"M Berger","year":"2013","unstructured":"Berger M, McCallus DE, Lin CS. Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies. J Peripher Nerv Syst. 2013;18:275\u201396.","journal-title":"J Peripher Nerv Syst."},{"key":"454_CR4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/157015909790031166","volume":"7","author":"S Jacob","year":"2009","unstructured":"Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol. 2009;7:337\u201342.","journal-title":"Curr Neuropharmacol."},{"key":"454_CR5","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","volume":"367","author":"EW Gelfand","year":"2012","unstructured":"Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012;367:2015\u201325.","journal-title":"N Engl J Med."},{"key":"454_CR6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S0317167100053932","volume":"31","author":"J Bakker","year":"2004","unstructured":"Bakker J, Metz L. Devic\u2019s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci. 2004;31:265\u20137.","journal-title":"Can J Neurol Sci."},{"key":"454_CR7","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2169\/internalmedicine.46.0217","volume":"46","author":"K Okada","year":"2007","unstructured":"Okada K, Tsuji S, Tanaka K. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med. 2007;46:1671\u20132.","journal-title":"Intern Med."},{"key":"454_CR8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nrl.2012.03.014","volume":"28","author":"MJ Magraner","year":"2013","unstructured":"Magraner MJ, Coret F, Casanova B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia. 2013;28:65\u201372.","journal-title":"Neurologia."},{"key":"454_CR9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014;20:501\u20134.","journal-title":"Mult Scler."},{"key":"454_CR10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.exer.2013.12.010","volume":"119","author":"Y Matsumoto","year":"2014","unstructured":"Matsumoto Y, Kanamori A, Nakamura M, Takahashi T, Nakashima I, Negi A. Sera from patients with seropositive neuromyelitis optica spectral disorders caused the degeneration of rodent optic nerve. Exp Eye Res. 2014;119:61\u20139.","journal-title":"Exp Eye Res."},{"key":"454_CR11","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1093\/brain\/awq105","volume":"133","author":"A Kanamori","year":"2010","unstructured":"Kanamori A, Catrinescu MM, Kanamori N, Mears KA, Beaubien R, Levin LA. Superoxide is an associated signal for apoptosis in axonal injury. Brain. 2010;133:2612\u201325.","journal-title":"Brain."},{"key":"454_CR12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.exer.2008.11.012","volume":"88","author":"A Kanamori","year":"2009","unstructured":"Kanamori A, Naka M, Fukuda M, Nakamura M, Negi A. Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Exp Eye Res. 2009;88:535\u201341.","journal-title":"Exp Eye Res."},{"key":"454_CR13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.expneurol.2014.03.004","volume":"255","author":"J Ratelade","year":"2014","unstructured":"Ratelade J, Smith AJ, Verkman AS. Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica. Exp Neurol. 2014;255:145\u201353.","journal-title":"Exp Neurol."},{"key":"454_CR14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010;133:349\u201361.","journal-title":"Brain."},{"key":"454_CR15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00401-013-1204-8","volume":"127","author":"N Asavapanumas","year":"2014","unstructured":"Asavapanumas N, Ratelade J, Verkman AS. Unique neuromyelitis optica pathology produced in naive rats by intracerebral administration of NMO-IgG. Acta Neuropathol. 2014;127:539\u201351.","journal-title":"Acta Neuropathol."},{"key":"454_CR16","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12:554\u201362.","journal-title":"Lancet Neurol."},{"key":"454_CR17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0090-1229(85)90027-3","volume":"34","author":"M Berger","year":"1985","unstructured":"Berger M, Rosenkranz P, Brown CY. Intravenous and standard immune serum globulin preparations interfere with uptake of 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity. Clin Immunol Immunopathol. 1985;34:227\u201336.","journal-title":"Clin Immunol Immunopathol."}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-016-0454-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-016-0454-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-016-0454-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T22:49:15Z","timestamp":1589669355000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-016-0454-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,7]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["454"],"URL":"https:\/\/doi.org\/10.1007\/s10384-016-0454-0","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,7]]}}}